Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors
Shots:
- The US FDA has granted FT designation to Chi-Med’s surufatinib for the treatment of both advanced and progressive pancreatic NET and non-pancreatic NET in patients who are not amenable for surgery
- Based on two P-III studies and ongoing P-Ib study, the company is planning for regulatory interactions in the US, EU and Japan. In Nov’2019, NMPA has accepted the NDA for the therapy to treat non-pancreatic NET and granted PR designation in Dec’2019
- Surufatinib is a novel, oral angio-immuno kinase inhibitor act by inhibiting the tyrosine kinase activity associated with VEGFR and FGFR and has received FDA’s ODD for pancreatic NET in Nov’2019
Click here to read full press release/ article | Ref: PRNewswire | Image: Chi-Med